Not FDA-approved1,6Evidence: Smaller human trialsNot a peptideMetabolic and weight · Brain, nerves and sleep

Tesofensine1

Also called NS23301

Not a peptide: a small molecule often looked up alongside peptides.

Key takeaway

Tesofensine is a small synthetic drug, not a peptide: a triple monoamine reuptake inhibitor that blocks the uptake of noradrenaline, dopamine and serotonin by nerve cells. It was first studied for Parkinson and Alzheimer disease, then for obesity.1,2,5 In a 24-week randomized trial of 203 adults with obesity, published in 2008, people taking it lost 4.5% to 10.6% of their body weight, compared with 2.0% on placebo; in 2013 the journal published an expression of concern about that report.2,3 No FDA approval is reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.1,6,8

Tesofensine at a glance

Substance typeNot a peptide. FDA’s substance registry records tesofensine as a chemical compound with the formula C17H23Cl2NO, and trial reports describe it as a monoamine reuptake inhibitor.1,2
What it isA synthetic inhibitor of the reuptake of noradrenaline, dopamine and serotonin, also coded NS2330, recorded by FDA’s substance registry as a chemical compound.1,2
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,6
Human evidencePhase 2 randomized trials: one in 203 adults with obesity, and trials in Parkinson and Alzheimer disease whose weight data were pooled.2,4,5
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is tesofensine?

Tesofensine is a synthetic chemical compound, not a peptide. FDA’s substance registry records it with the formula C17H23Cl2NO and the code name NS2330.1

Researchers describe it as an inhibitor of the uptake of noradrenaline, dopamine and serotonin by nerve cells, a so-called triple monoamine reuptake inhibitor.2,5

How is tesofensine thought to work?

It blocks the presynaptic uptake of noradrenaline, dopamine and serotonin, three chemical messengers in the brain, according to the 2008 trial report.2

A pooled analysis of weight data from its Parkinson and Alzheimer disease trials found weight loss, and its authors wrote that it was then being developed for obesity.4

What do human studies show?

A 2008 randomized, double-blind trial assigned 203 adults with obesity, all on a reduced-calorie diet, to one of three strengths of tesofensine or placebo for 24 weeks. Average weight loss was 4.5%, 9.2% and 10.6% with tesofensine and 2.0% with placebo; heart rate rose by about 7 beats per minute at the middle strength.2

The most common side effects in that trial were dry mouth, nausea, constipation, diarrhoea and insomnia. The authors said the results needed confirmation in phase 3 trials.2

In 2013 The Lancet published an expression of concern about the 2008 report.3

In four randomized trials in Parkinson or Alzheimer disease, people on tesofensine lost up to about 3% of their weight over 14 weeks without any diet program, and heart rate rose with strength, according to a pooled analysis.4

What the evidence base contains

  • Controlled human trial A 24-week phase 2 randomized, double-blind, placebo-controlled trial in 203 adults with obesity at five Danish centres, which reported greater weight loss than placebo and a higher heart rate at one strength; the journal later published an expression of concern about the report.2,3
  • Controlled human trial A pooled analysis of weight change in four randomized, double-blind trials in Parkinson or Alzheimer disease, which compared 740 people on tesofensine with 228 on placebo for 14 weeks.4
  • Controlled human trial ADVANS (NCT00148512): a 14-week phase 2 randomized, placebo-controlled trial in advanced Parkinson disease, which found modest improvements at some strengths but no clear relationship between strength and benefit.5

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is tesofensine FDA-approved?

None of the sources reviewed here reports an approval of tesofensine by FDA.1,6

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list tesofensine.6

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Tesofensine is not among them.7,8

Timeline

  1. The ADVANS trial of tesofensine in advanced Parkinson disease is published.5
  2. A randomized trial of tesofensine in 203 adults with obesity is published in The Lancet.2
  3. The Lancet publishes an expression of concern about the 2008 obesity trial report.3

What is still unknown?

Whether its effect on weight holds up in larger, longer trials: the sources reviewed here describe phase 2 trials of up to 24 weeks, and the main obesity report is subject to an expression of concern.2,3

Its effect on the heart over time, since the trials reported a rise in heart rate.2,4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Tesofensine: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Tesofensine are a bounded selection, not every registration or paper about Tesofensine. For the years before Tesofensine was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Tesofensine as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Tesofensine in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; studied in clinical trials. A 24-week trial in 203 adults with obesity reported weight loss, but the journal later published an expression of concern about the report. Tesofensine is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Tesofensine?

No FDA approval reported; studied in clinical trials. A 24-week trial in 203 adults with obesity reported weight loss, but the journal later published an expression of concern about the report. Tesofensine is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
8
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.↗Source date September 3, 2026
  2. Clinical trials · added November 16, 2026

    ClinicalTrials.gov record NCT03149445↗Source date February 26, 2024
  3. Literature metadata · added November 16, 2026

    Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.↗Source date October 20, 2021

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Tesofensine?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

11Selected dated records
19Connected citations
8Populated source years2008–2026
2/4Record lanes present

Registered human studies

Trial composition

7 of 7 selected trial records include at least one phase value; 7 of 7 include a status value in the retained structured contract.

PhasesPhase 2 6Phase 1 2
Status at observationCompleted 7

PubMed bibliography

Publication composition

4 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 4Research Support, Non-U.S. Gov't 3Randomized Controlled Trial 2Comparative Study 1Controlled Clinical Trial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
11

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 11 dated records

Research hub

Explore the Tesofensine evidence record

Open all 11 records →
11Dated records
2Evidence types
11Cited public sources
8Source years

Change ledger

Recently changed for Tesofensine

Open all 11 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00006077

PeptideScanner retained ClinicalTrials.gov record NCT00006077 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was tesofensine.

PeptideScanner change date
November 16, 2026
Cited source date
March 4, 2008
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00394667

PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine.

PeptideScanner change date
November 16, 2026
Cited source date
April 22, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00428415

PeptideScanner retained ClinicalTrials.gov record NCT00428415 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-05, and PeptideScanner's reviewed identity mapping was tesofensine.

PeptideScanner change date
November 16, 2026
Cited source date
March 5, 2008
Evidence lane
Clinical trials

Official-source collections

Source records for Tesofensine

Open the full research atlas →
PubMed4

4 with attributed title, venue, publication-date, and type metadata.

  1. Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.Drug testing and analysis · 2026 06 19
  2. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.Clinical pharmacokinetics · 2009
  3. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.British journal of pharmacology · 2007 11 05
Explore all selected literature →
ClinicalTrials.gov7

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT03149445Registry update February 26, 2024 · completed at observation
  2. NCT02737891Registry update May 14, 2020 · completed at observation
  3. NCT03286829Registry update May 14, 2020 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span March 4, 2008 to September 3, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,6
  • U.S. Department of Health and Human Services7
Dated updates connected to this profile · 11

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine.↗

    PubMed lists PMID 42320973 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-06-19 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT03149445↗

    PeptideScanner retained ClinicalTrials.gov record NCT03149445 at 2026-11-16T17:29:46.323Z. Its registry update date was 2024-02-26, and PeptideScanner's reviewed identity mapping was tesofensine.↗

  3. Literature metadata

    Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.↗

    PubMed lists PMID 17982477 in British journal of pharmacology as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-11-05 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.↗

    PubMed lists PMID 19705923 in Clinical pharmacokinetics as Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2009 (year precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT02737891↗

    PeptideScanner retained ClinicalTrials.gov record NCT02737891 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT03286829↗

    PeptideScanner retained ClinicalTrials.gov record NCT03286829 at 2026-11-16T17:29:46.323Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was tesofensine.↗

  7. Literature metadata

    Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.↗

    PubMed lists PMID 17324246 in British journal of clinical pharmacology as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-02-23 (day precision). PeptideScanner associated the retained record with the identity slug tesofensine. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT00394667↗

    PeptideScanner retained ClinicalTrials.gov record NCT00394667 at 2026-11-16T17:29:46.323Z. Its registry update date was 2013-04-22, and PeptideScanner's reviewed identity mapping was tesofensine.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT00481104↗

    PeptideScanner retained ClinicalTrials.gov record NCT00481104 at 2026-11-16T17:29:46.323Z. Its registry update date was 2011-07-04, and PeptideScanner's reviewed identity mapping was tesofensine.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT00428415↗

    PeptideScanner retained ClinicalTrials.gov record NCT00428415 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-05, and PeptideScanner's reviewed identity mapping was tesofensine.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT00006077↗

    PeptideScanner retained ClinicalTrials.gov record NCT00006077 at 2026-11-16T17:29:46.323Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was tesofensine.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Tesofensine substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (2008) · PMID 18950853 ↗

    The Lancet · Official source · Source checked November 16, 2026

  3. 3
    Expression of concern—effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial (2013) · PMID 23561987 ↗

    The Lancet · Official source · Source checked November 16, 2026

  4. 4
    Weight loss produced by tesofensine in patients with Parkinson’s or Alzheimer’s disease (2008) · PMID 18356831 ↗

    Obesity · Official source · Source checked November 16, 2026

  5. 5
    Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study (2008) · PMID 18474731 ↗

    Archives of Neurology · Official source · Source checked November 16, 2026

  6. 6
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026